Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Cost-effectiveness analysis: a reader's guide].

A Vergnenègre1

  • 1Service de l'Information Médicale et de l'Evaluation, Hôpital du Cluzeau, CHU Dupuytren, Limoges cedex, France. avergne@unilim.fr

Revue Des Maladies Respiratoires
|April 24, 2003
PubMed
Summary

This study critically appraises cost-effectiveness analysis in thoracic oncology, evaluating chemotherapy regimens for stage IV non-small cell lung cancer. A methodological guide helps assess the validity of cost-effectiveness results.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patients with non-small-cell lung cancer harbouring a <i>BRAF</i> mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

Current oncology (Toronto, Ont.)·2018
Same author

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

BMC cancer·2015
Same author

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.

Targeted oncology·2015
Same author

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.

Lung cancer (Amsterdam, Netherlands)·2014
Same author

Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study.

Current medical research and opinion·2013

Area of Science:

  • Oncology
  • Health Economics

Background:

  • Cost-effectiveness analysis (CEA) is crucial for healthcare decision-making.
  • This article critically appraises CEA methodology.
  • Focuses on thoracic oncology treatment choices.

Observation:

  • Compares three first-line chemotherapy regimens for stage IV non-small cell bronchial carcinoma: vinorelbine alone, cisplatin-vinorelbine, and cisplatin-vindesine.
  • Applies a specific guide to evaluate the methodology and results of CEA.

Findings:

  • The chosen guide enables a thorough evaluation of the cost-effectiveness analysis methodology.
  • This assessment ensures the validity and reliability of the obtained results.

Implications:

  • The findings can be applied to guide clinical decisions for patients with non-small cell lung cancer.

Related Experiment Videos

  • Highlights the importance of critically appraising CEA and considering its limitations in clinical practice.